These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8171337)

  • 1. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
    Renner C; Jung W; Sahin U; Denfeld R; Pohl C; Trümper L; Hartmann F; Diehl V; van Lier R; Pfreundschuh M
    Science; 1994 May; 264(5160):833-5. PubMed ID: 8171337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.
    Renner C; Bauer S; Sahin U; Jung W; van Lier R; Jacobs G; Held G; Pfreundschuh M
    Blood; 1996 Apr; 87(7):2930-7. PubMed ID: 8639913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.
    da Costa L; Renner C; Hartmann F; Pfreundschuh M
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S33-6. PubMed ID: 10950145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
    Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
    Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies.
    Renner C; Pfreundschuh M
    J Hematother; 1995 Oct; 4(5):447-51. PubMed ID: 8581383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
    Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
    Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28.
    Renner C; Ohnesorge S; Held G; Bauer S; Jung W; Pfitzenmeier JP; Pfreundschuh M
    Blood; 1996 Jul; 88(1):236-41. PubMed ID: 8704179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
    Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
    J Immunother; 1997 Sep; 20(5):325-33. PubMed ID: 9336739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo.
    Bauer S; Renner C; Juwana JP; Held G; Ohnesorge S; Gerlach K; Pfreundschuh M
    Cancer Res; 1999 Apr; 59(8):1961-5. PubMed ID: 10213507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody.
    Renner C; Hartmann F; Jung W; Deisting C; Juwana M; Pfreundschuh M
    Cancer Immunol Immunother; 2000 Jun; 49(3):173-80. PubMed ID: 10881697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Hodgkin's disease with bispecific antibodies.
    Hartmann F; Renner C; Jung W; Sahin U; Pfreundschuh M
    Ann Oncol; 1996; 7 Suppl 4():143-6. PubMed ID: 8836426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
    Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
    Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
    Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
    Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
    Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
    Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.
    Grosse-Hovest L; Brandl M; Dohlsten M; Kalland T; Wilmanns W; Jung G
    Int J Cancer; 1999 Jan; 80(1):138-44. PubMed ID: 9935244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies.
    Renner C; Jung W; Sahin U; van Lier R; Pfreundschuh M
    Eur J Immunol; 1995 Jul; 25(7):2027-33. PubMed ID: 7621876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity.
    Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
    Clin Exp Immunol; 1997 May; 108(2):352-7. PubMed ID: 9158110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors.
    Arndt MA; Krauss J; Kipriyanov SM; Pfreundschuh M; Little M
    Blood; 1999 Oct; 94(8):2562-8. PubMed ID: 10515858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma.
    Manzke O; Titzer S; Tesch H; Diehl V; Bohlen H
    Cancer Immunol Immunother; 1997; 45(3-4):198-202. PubMed ID: 9435873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.